



ASX release

23 January 2018

AtCor's XCEL Device Clinically Validated in Third Party Independent Study

Further solidifies AtCor's technology as the gold standard for non-invasive measurement of arterial stiffness and central blood pressures

AtCor Medical (ASX: ACG), the developer and marketer of SphygmoCor® for advanced hypertension management, today announced the publication of a new study in the Journal *Hypertension Research*, the official journal of the Japanese Society of Hypertension. The article "Validity of the augmentation index and pulse pressure amplification as determined by the SphygmoCor XCEL device; a comparison with invasive measurements" showed a strong correlation between non-invasive SphygmoCor XCEL measurements and traditional invasive measures. The study was completely independent of AtCor and only made known to the company after the results were published.

In the study central aortic pressures and indices derived non-invasively by SphygmoCor XCEL were compared with invasive measurements. Central augmentation index and pulse pressure amplification which are key measures of arterial stiffness and adverse load on the heart were evaluated. Both measures are important targets for disease prevention and treatment and, when not properly addressed, are highly correlated with and pose significant risk for adverse cardiovascular events and outcomes. The study included a broad range of values and ages (23-88 years) with results applicable to a wide range of the adult population.

The authors stated: "In conclusion, we demonstrated the validity of the SphygmoCor XCEL device in measuring the augmentation and amplification parameters against invasive measurements". The results were robust with a P-value<0.001.

AtCor's Chief Executive Officer, Craig Cooper, said: "This is a significant independent validation of our SphygmoCor XCEL central measures related to arterial stiffness and cardiac load and we are delighted by the results. The study further solidifies our strong patent protected position as the only medical device company which can accurately produce - non-invasively through a traditional blood pressure cuff - the central waveform and measures equivalent to those measured by an invasive pressure catheter placed at the heart. The value of this information is compelling for prevention, early intervention, and effective disease management."

About AtCor Medical

AtCor Medical develops and markets products for the early detection of arterial stiffness, target organ damage and management of cardiovascular and renal disease. Its technology allows researchers and clinicians to noninvasively measure the central arterial pressure waveform, central aortic pressures and pulse wave velocity. Central arterial pressure waveform analysis, as measured by the company's SphygmoCor system, provides clinicians with better diagnostic and prognostic information to determine the need for and type of interventions, effects which cannot be detected with standard brachial blood pressure measurements.

More than 4,000 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 1,000 peer-reviewed studies published in leading medical journals and thousands of citations. AtCor Medical has operations in Australia, the United States, and Europe.

For further information, please contact:

Duncan Ross
+1 (630) 228 8873

Peter Manley
+61 (2) 8815 8811

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au